Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Biosyent Inc BIOYF


Primary Symbol: V.RX

BioSyent Inc. is a specialty pharmaceutical company. The Company, through its wholly owned subsidiaries, BioSyent Pharma Inc., and BioSyent Pharma International Inc., acquires or licenses and develops pharmaceutical and other healthcare products for sale in Canada and certain international markets. Hedley Technologies Ltd., a wholly owned subsidiary operates the Company’s business marketing biologically and health friendly non-chemical insecticides. Its products include Combogesic, Cathejell, FeraMAX Pd Therapeutic 150, FeraMAX Pd Maintenance 45, FeraMAX Pd Powder 15, Gelclair, Inofolic, Proktis-M, RepaGyn, and Tibella. Combogesic is for the short-term management of mild to moderate acute pain and the reduction of fever in adults. Cathejell combines sterile gel and 2% lidocaine jelly in a collapsible syringe that is ready to use. FeraMAX Pd Therapeutic 150 is an oral hematinic that helps the body form red blood cells and is indicated for the treatment of iron deficiency anemia.


TSXV:RX - Post by User

Comment by overnouton Dec 17, 2020 9:19am
175 Views
Post# 32126825

RE:Top Gainers

RE:Top GainersIt is hard to imagine volume picking up in any kind of considerble way. With a float of only 9.4M shares and the NCIB further reducing float count by 900K this ends up being a very illiquid stock.

With the cash that is being generated and the new products coming on stream, I believe that existing shareholders will be rewarded for holding, but where would the volume come from?

This would be hard for institutions to take any significant position in, although one seems to have recently taken a position on that 400K share day, but the stock price didn't budge, leading me to think it was a hand-off of a block from one to another at a set price.

Perhaps if the shares got over $10, they could split the shares. Seems laughable to split at $10, but it would double the share count which might provide some liquidity going forward.
<< Previous
Bullboard Posts
Next >>